Celldex Therapeutics, Inc. (CLDX) Cash Flow Statement

The OCF/NI ratio consistently below 1.0 suggests that net losses overstate cash consumption, as SBC and D&A are non-cash. However, the gap is modest, implying that the majority of losses are cash-based, primarily R&D expenditures. Investors should monitor whether this ratio deteriorates as trial costs escalate.

The FCF margin is deeply negative and increasingly so, with the latest quarter showing -2754% due to minimal revenue. This trajectory indicates that the company is consuming capital at an accelerating rate, with no near-term revenue to offset the burn. The trend aligns with the transition to late-stage trials, which typically require substantial upfront investment.

The low capital intensity is typical for a clinical-stage biotech, where R&D spending, not capex, drives value creation. The slight uptick in 2026Q2 to $3.2M may indicate initial investments in manufacturing or lab capacity, but it remains immaterial relative to operating burn. This suggests that the company's cash needs are dominated by clinical trial costs, not fixed asset replacement.

The volatility in working capital adjustments suggests that the company's cash burn is not smooth, but rather lumpy, depending on the stage of clinical trials and the settlement of payables. Positive adjustments in recent quarters may indicate delayed payments, which could reverse and pressure future cash flows. This warrants monitoring for potential liquidity constraints.

The absence of shareholder returns is expected for a clinical-stage biotech, but it underscores that the company is entirely dependent on external financing to fund its operations. With no debt on the balance sheet, the company appears to rely on equity issuance, which could lead to dilution. Investors should monitor the pace of cash consumption relative to financing activities.

The cumulative gap between net income and operating cash flow suggests that while non-cash items like SBC and D&A inflate losses, the majority of the company's cash consumption is real and tied to clinical development. This divergence is typical for biotechs, but the magnitude of the gap relative to the company's cash position is concerning, as it implies that the reported cash balance may not fully reflect the ongoing cash needs.